Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov;199(4):477-479.
doi: 10.1111/bjh.18402. Epub 2022 Aug 9.

What complements complement in transplant-associated thrombotic microangiopathy?

Anthony Sabulski  1   2 , Sonata Jodele  1   2
Affiliations

What complements complement in transplant-associated thrombotic microangiopathy?

Anthony Sabulski et al. Br J Haematol. 2022 Nov.

Abstract

Transplant-associated thrombotic microangiopathy remains a lethal complication of haematopoietic stem cell transplant and not all patients respond to terminal complement inhibitors. Qi et al. show that hypoxia-inducible factor-1α (HIF-1α) may be a previously unrecognized driver of this endothelial injury syndrome. Commentary on Qi et al. Upregulation of HIF-1α contributes to complement activation in transplantation-associated thrombotic microangiopathy. Br J Haematol. 2022 199:603-615.

Keywords: endothelial injury; hypoxia-inducible factor-1α; thrombotic microangiopathy.

PubMed Disclaimer

References

REFERENCES

    1. Jodele S, Davies SM, Lane A, Khoury J, Dandoy C, Goebel J, et al. Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults. Blood. 2014;124(4):645-53. https://doi.org/10.1182/blood-2014-03-564997
    1. Jodele S, Dandoy CE, Lane A, Laskin BL, Teusink-Cross A, Myers KC, et al. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab. Blood. 2020;135(13):1049-57. https://doi.org/10.1182/blood.2019004218
    1. Jodele S, Dandoy CE, Sabulski A, Koo J, Lane A, Myers KC, et al. TA-TMA risk stratification: is there a window of opportunity to improve outcomes? Transplant Cell Ther. 2022;28(7):392.e1-9. https://doi.org/10.1016/j.jtct.2022.04.019
    1. Higham CS, Collins G, Shimano KA, Melton A, Kharbanda S, Winestone LE, et al. Transplant-associated thrombotic microangiopathy in pediatric patients: pre-HSCT risk stratification and prophylaxis. Blood Adv. 2021;5(8):2106-14. https://doi.org/10.1182/bloodadvances.2020003988
    1. Jodele S, Sabulski A. Transplant-associated thrombotic microangiopathy: elucidating prevention strategies and identifying high-risk patients. Expert Rev Hematol. 2021;14(8):751-63. https://doi.org/10.1080/17474086.2021.1960816

Substances

LinkOut - more resources